Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of March 2026, specifically detailing a share repurchase executed on March 6, 2026. The company is a global biopharma firm headquartered in London, England.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this document).
- Shares Purchased: 690,000 ordinary shares of 31¼ pence each.
- Transaction Date: March 6, 2026.
- Price Range: Lowest price paid was 2,029.00 GBp; highest price paid was 2,080.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,048.95 GBp.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON (London Stock Exchange).
- Treasury Share Holdings: Following this purchase, GSK holds 247,047,094 ordinary shares in treasury.
- Shares in Issue: 4,069,121,728 ordinary shares (excluding treasury shares).
- Treasury Voting Rights: 6.07% of total voting rights.
Material Changes and Program Status
This purchase is part of GSK's existing buyback programme, executed pursuant to a non-discretionary agreement with broker BNP Paribas SA announced on February 17, 2026. Since the commencement of this specific agreement on February 17, 2026, the company has purchased an aggregate of 7,156,000 ordinary shares. The filing does not provide comparative financial data against prior periods as it is a transaction report.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future earnings or operational outlook. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections. Investors are directed to the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025 for a detailed description of these risks.
Key Facts for Investor Verification
- Verify the total remaining authorization under the current buyback programme to assess future capital return capacity.
- Confirm the impact of the 6.07% treasury share holding on earnings per share (EPS) calculations and voting rights.
- Review the "Risk Factors" in the 2025 Form 20-F as referenced in the cautionary statement.
- Note that the filing does not contain revenue, profit, or cash flow data; these metrics must be sourced from the company's most recent quarterly or annual reports.